Chrissy Teigen says she used Ozempic after a pregnancy loss

Chrissy Teigen said in a September 2025 episode of her podcast, Self-Conscious, that she turned to Ozempic while dealing with depression after her 2020 miscarriage ^[1]. She described the period as a "deep depression of seeing this pregnant belly with no baby in it" ^[1].

Teigen said her body felt stuck after the loss. "My body was completely stuck," she said. "I really let myself indulge when I was pregnant. So, when I had lost that baby at 20 weeks, I had probably gained an extra 40 pounds that I wasn't comfortable with" ^[1]. She said she used the drug in that context to try to manage her weight during a difficult emotional stretch.

She also spoke about a common side effect of GLP-1 medications: a sharp drop in hunger cues. "It was frustrating for me because I know that logically you need food to have energy," she said, describing the disconnect between knowing she needed to eat and not feeling hungry ^[1].

Ozempic's active ingredient is semaglutide, which is approved by the FDA to treat type 2 diabetes. The same drug is approved for obesity under the brand name Wegovy. Because of its weight-loss effect, Ozempic is frequently prescribed off-label for weight loss, though Novo Nordisk, the company that makes it, has said it does not support that off-label use ^[1].

Teigen's comments follow a string of celebrities, including Oprah Winfrey, Kelly Clarkson, Vanessa Williams, Rosie O'Donnell and Serena Williams, who have discussed their own experiences with GLP-1 drugs in the past two years ^[1]. Not all of these accounts have been positive: podcaster Bunnie XO told People in December 2025 that she experienced a "bout of suicidal ideation" while taking a GLP-1 drug, calling it one of the darkest periods of her life ^[1].

Why it matters for patients

Teigen's account adds a mental health dimension to the public conversation about GLP-1 drugs that is separate from the more familiar debates over cost and access. She used the medication during a period of grief and depression tied to pregnancy loss, which is a use case distinct from the type 2 diabetes and obesity indications the drug is actually approved for.

Her description of losing hunger cues echoes a known effect of GLP-1 medications: they slow digestion and reduce appetite, which is part of how they produce weight loss. In clinical trials, semaglutide has been shown to produce substantial weight loss over time, with one dataset showing an average loss of about 12.7 kilograms, or nearly 28 pounds, over 68 weeks compared with a placebo ^[2]. But appetite suppression that feels disorienting, as Teigen described, is a real and reported experience, not just a side note.

The sources here do not say whether Teigen used the drug under a doctor's supervision, how long she stayed on it, or what dose she took. They also do not address whether starting a GLP-1 drug during active depression or grief carries added risks, an area not covered by the reporting reviewed for this story. Bunnie XO's separate account of suicidal ideation while on a GLP-1 drug shows that mental health effects can vary widely between users, and the sources do not offer a clear consensus on how common or predictable such effects are.

For patients considering these drugs, Teigen's story is a reminder that GLP-1 medications affect appetite and body signals in ways that can feel unfamiliar, and that people may turn to them during emotionally difficult times for reasons beyond diabetes or standard weight management goals.